A Phase 3 trial of Amylyx Pharmaceuticals’ ALS drug, Relyvrio, failed to show benefit compared to placebo, disappointing the ALS community. Previous positive results from a Phase 2 study did not replicate in a larger group, impacting patients like Gwen Petersen, who saw stabilization on the drug. Concerns arise about insurance coverage and future ALS drug development. Despite setbacks, patients like John Russo and Phil Green maintain hope and emphasize the need for individualized treatments. Katrina Byrd highlights the challenges of drug affordability and the relentless nature of ALS, but finds strength in the patient community’s resilience. The trial outcome underscores the ongoing struggle for effective ALS treatments.
Source link
Relyvrio patients react with fear, worry
